Polymorphisms of IL-17 and ICAM-1 and their expression in Guillain–Barré syndrome

Abstract

Purpose: Guillain–Barré syndrome (GBS) is an acute inflammatory, autoimmune disorder of peripheral nervous system. Interleukin-17 (IL-17) and intercellular adhesion molecule-1 (ICAM-1) polymorphisms with higher expression levels have already been studied in many inflammatory and autoimmune diseases. However, the possible role of IL-17 and ICAM-1 polymorphisms in GBS remains unknown. Therefore, the current study investigated IL-17 (His161Arg and Glu126Gly) and ICAM-1 (Gly241Arg) polymorphisms. Materials and method: In this study, total 80 GBS patients and 75 normal healthy controls were included. IL-17 (His161Arg and Glu126Gly) and ICAM-1 (Gly241Arg) polymorphisms were performed using polymerase chain reaction –restriction fragment length polymorphism analysis. Further, the expression of ICAM-1 and IL-17 was determined by reverse-transcriptase PCR and enzyme-linked immunosorbent assay. Results: IL-17 (Glu126Gly) mutant and ICAM-1 (Gly241Arg) heterozygous genotypes were strongly associated with increased risk of GBS (p < 0.016; OR = 3.706, 95% CI = 1.28–10.67; p < 0.001; OR = 4.148, 95% CI = 2.119–8.119, respectively). IL-17 and ICAM-1 genes showed significantly higher expression in GBS when compared with healthy controls. Conclusion: IL-17 and ICAM-1 polymorphisms showed significant association with GBS and their enhanced expressions have possible role in GBS development. IL-17 and ICAM-1 polymorphisms could be genetic markers to GBS susceptibility.

KEYWORDS:

• Guillain–Barré syndrome
• gene polymorphism
• cytokine IL-17 and adhesion molecule
• ICAM-1

Acknowledgements

Nagendra Kumar Kharwar duly acknowledges the financial assistance from Indian Council of Medical Research (File No. 3/1/2/12-2010-NCD-I).

Declaration of Interest

No potential conflict of interest was reported by the authors.

Indian Council of Medical Research [file number 3/1/2/12-2010-NCD-I].